| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 56 | 2024 | 1065 | 7.640 |
Why?
|
| Acute Chest Syndrome | 8 | 2022 | 32 | 2.370 |
Why?
|
| Hydroxyurea | 14 | 2020 | 284 | 2.180 |
Why?
|
| Antisickling Agents | 10 | 2020 | 72 | 2.090 |
Why?
|
| Anemia, Sideroblastic | 10 | 2021 | 112 | 1.840 |
Why?
|
| Iron Overload | 6 | 2015 | 246 | 1.180 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2022 | 2763 | 1.120 |
Why?
|
| Iron | 6 | 2018 | 1814 | 0.860 |
Why?
|
| beta-Thalassemia | 4 | 2018 | 236 | 0.840 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2018 | 372 | 0.840 |
Why?
|
| Iron Chelating Agents | 5 | 2018 | 141 | 0.740 |
Why?
|
| Pain | 10 | 2023 | 5100 | 0.710 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2021 | 170 | 0.680 |
Why?
|
| Genetic Diseases, X-Linked | 6 | 2018 | 391 | 0.600 |
Why?
|
| Erythrocyte Membrane | 1 | 2018 | 438 | 0.550 |
Why?
|
| Drugs, Investigational | 1 | 2018 | 212 | 0.520 |
Why?
|
| Neonatal Screening | 2 | 2016 | 619 | 0.510 |
Why?
|
| Serine Endopeptidases | 2 | 2018 | 1027 | 0.470 |
Why?
|
| Iron Metabolism Disorders | 1 | 2014 | 24 | 0.460 |
Why?
|
| Hospitals, Pediatric | 4 | 2022 | 1876 | 0.450 |
Why?
|
| Phlebotomy | 3 | 2015 | 138 | 0.450 |
Why?
|
| Fetal Hemoglobin | 3 | 2020 | 346 | 0.440 |
Why?
|
| Spherocytosis, Hereditary | 3 | 2019 | 83 | 0.400 |
Why?
|
| Child | 51 | 2024 | 80960 | 0.380 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 914 | 0.380 |
Why?
|
| Hemoglobin, Sickle | 3 | 2008 | 113 | 0.370 |
Why?
|
| Splenectomy | 3 | 2019 | 392 | 0.360 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 4 | 2024 | 279 | 0.360 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 1399 | 0.360 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2023 | 117 | 0.360 |
Why?
|
| Vascular Diseases | 2 | 2016 | 1163 | 0.350 |
Why?
|
| Hemoglobins, Abnormal | 2 | 2007 | 119 | 0.350 |
Why?
|
| Child, Preschool | 32 | 2024 | 42683 | 0.330 |
Why?
|
| Mutation | 7 | 2021 | 30266 | 0.320 |
Why?
|
| Genotype | 5 | 2021 | 13048 | 0.320 |
Why?
|
| Serratia Infections | 1 | 2008 | 8 | 0.320 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2016 | 285 | 0.300 |
Why?
|
| Cephalosporins | 1 | 2008 | 200 | 0.290 |
Why?
|
| Thrombasthenia | 1 | 2007 | 21 | 0.290 |
Why?
|
| Globins | 2 | 2007 | 405 | 0.280 |
Why?
|
| Adolescent | 42 | 2024 | 89244 | 0.280 |
Why?
|
| Glucuronosyltransferase | 2 | 2005 | 136 | 0.260 |
Why?
|
| Phenotype | 6 | 2021 | 16731 | 0.260 |
Why?
|
| Homeostasis | 3 | 2014 | 3347 | 0.250 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 147 | 0.250 |
Why?
|
| Humans | 93 | 2024 | 768970 | 0.240 |
Why?
|
| Anemia, Aplastic | 1 | 2007 | 231 | 0.240 |
Why?
|
| Chelation Therapy | 2 | 2013 | 77 | 0.240 |
Why?
|
| Blood Transfusion | 4 | 2018 | 1309 | 0.240 |
Why?
|
| Erythrocyte Transfusion | 4 | 2017 | 575 | 0.230 |
Why?
|
| Double-Blind Method | 5 | 2019 | 12467 | 0.220 |
Why?
|
| Bilirubin | 4 | 2017 | 438 | 0.220 |
Why?
|
| Ketorolac | 1 | 2024 | 95 | 0.220 |
Why?
|
| Cholelithiasis | 1 | 2005 | 408 | 0.210 |
Why?
|
| Neutropenia | 1 | 2008 | 893 | 0.210 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1445 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2018 | 7885 | 0.210 |
Why?
|
| Hemoglobins | 4 | 2018 | 1531 | 0.210 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2003 | 100 | 0.200 |
Why?
|
| Male | 57 | 2024 | 365203 | 0.200 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2003 | 96 | 0.200 |
Why?
|
| Female | 57 | 2024 | 397515 | 0.200 |
Why?
|
| Data Collection | 1 | 2011 | 3324 | 0.190 |
Why?
|
| Hemoglobinopathies | 1 | 2002 | 101 | 0.190 |
Why?
|
| Anemia, Hemolytic, Congenital | 2 | 2014 | 71 | 0.190 |
Why?
|
| Mitochondrial Proteins | 2 | 2018 | 980 | 0.180 |
Why?
|
| Indenes | 1 | 2021 | 59 | 0.180 |
Why?
|
| Granulocytes | 1 | 2003 | 551 | 0.180 |
Why?
|
| Polycythemia | 1 | 2021 | 124 | 0.180 |
Why?
|
| Deferoxamine | 2 | 2018 | 155 | 0.180 |
Why?
|
| Paraganglioma | 1 | 2021 | 143 | 0.170 |
Why?
|
| gamma-Globins | 1 | 2020 | 105 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2014 | 550 | 0.170 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2020 | 50 | 0.170 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 425 | 0.170 |
Why?
|
| Ketamine | 2 | 2023 | 527 | 0.170 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 246 | 0.160 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 1547 | 0.160 |
Why?
|
| Infant | 17 | 2021 | 36556 | 0.160 |
Why?
|
| Benzoates | 3 | 2015 | 213 | 0.160 |
Why?
|
| Infant, Newborn | 11 | 2021 | 26428 | 0.160 |
Why?
|
| Glycocalyx | 1 | 2020 | 99 | 0.160 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 2018 | 10 | 0.160 |
Why?
|
| Bone Marrow Diseases | 1 | 2020 | 234 | 0.160 |
Why?
|
| Hydromorphone | 1 | 2019 | 70 | 0.150 |
Why?
|
| Ankyrins | 2 | 2018 | 123 | 0.150 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2018 | 54 | 0.150 |
Why?
|
| MELAS Syndrome | 1 | 2018 | 56 | 0.150 |
Why?
|
| Analgesics, Opioid | 4 | 2023 | 3838 | 0.150 |
Why?
|
| Reticulocytosis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Patient Readmission | 2 | 2011 | 3313 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 1737 | 0.140 |
Why?
|
| Blood Component Removal | 1 | 2018 | 132 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2018 | 225 | 0.140 |
Why?
|
| Alu Elements | 1 | 2018 | 115 | 0.140 |
Why?
|
| Anemia, Neonatal | 1 | 2017 | 19 | 0.140 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 245 | 0.140 |
Why?
|
| Hemorrhage | 2 | 2022 | 3466 | 0.140 |
Why?
|
| Stroke | 9 | 2024 | 9756 | 0.140 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 1 | 2018 | 50 | 0.140 |
Why?
|
| Acidosis, Lactic | 1 | 2018 | 145 | 0.140 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2018 | 56 | 0.140 |
Why?
|
| Erythroblasts | 1 | 2016 | 142 | 0.130 |
Why?
|
| Isoelectric Focusing | 1 | 2016 | 149 | 0.130 |
Why?
|
| Sickle Cell Trait | 2 | 2007 | 86 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 735 | 0.130 |
Why?
|
| Fever | 2 | 2014 | 1619 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 4251 | 0.130 |
Why?
|
| Pyruvate Kinase | 1 | 2018 | 190 | 0.130 |
Why?
|
| Mutagenesis, Insertional | 2 | 2018 | 662 | 0.130 |
Why?
|
| Pediatrics | 1 | 2011 | 3628 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 763 | 0.130 |
Why?
|
| Laboratories | 1 | 2019 | 463 | 0.130 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 1887 | 0.130 |
Why?
|
| Liberia | 1 | 2016 | 176 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1143 | 0.120 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2010 | 353 | 0.120 |
Why?
|
| Reticulocyte Count | 3 | 2017 | 36 | 0.120 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 153 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 878 | 0.120 |
Why?
|
| Triazoles | 3 | 2015 | 904 | 0.120 |
Why?
|
| Developmental Disabilities | 2 | 2014 | 1520 | 0.120 |
Why?
|
| Platelet Function Tests | 1 | 2016 | 275 | 0.120 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 518 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 2258 | 0.120 |
Why?
|
| RNA Nucleotidyltransferases | 1 | 2014 | 60 | 0.120 |
Why?
|
| Pain Measurement | 3 | 2021 | 3586 | 0.120 |
Why?
|
| Morphine | 1 | 2019 | 658 | 0.120 |
Why?
|
| Secondary Prevention | 3 | 2014 | 1476 | 0.120 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 321 | 0.120 |
Why?
|
| Blood Platelets | 2 | 2016 | 2479 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2276 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 7478 | 0.110 |
Why?
|
| GATA Transcription Factors | 1 | 2013 | 29 | 0.110 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2592 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2022 | 2025 | 0.110 |
Why?
|
| 5-Aminolevulinate Synthetase | 1 | 2013 | 66 | 0.110 |
Why?
|
| Base Sequence | 5 | 2018 | 12430 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 395 | 0.110 |
Why?
|
| Piperazines | 2 | 2015 | 2553 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2009 | 7460 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2007 | 3301 | 0.110 |
Why?
|
| Research Design | 3 | 2019 | 6214 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2015 | 4040 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 872 | 0.100 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2015 | 489 | 0.100 |
Why?
|
| Familial Mediterranean Fever | 1 | 2013 | 65 | 0.100 |
Why?
|
| Biological Assay | 1 | 2015 | 628 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2018 | 3408 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2020 | 2986 | 0.100 |
Why?
|
| RNA Interference | 1 | 2020 | 2835 | 0.100 |
Why?
|
| Sequence Deletion | 1 | 2016 | 1498 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2024 | 1936 | 0.100 |
Why?
|
| Quality Improvement | 2 | 2024 | 3860 | 0.100 |
Why?
|
| Young Adult | 16 | 2023 | 60131 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10765 | 0.090 |
Why?
|
| Hospitalization | 1 | 2011 | 10847 | 0.090 |
Why?
|
| Introns | 1 | 2013 | 969 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 899 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 1608 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2016 | 965 | 0.090 |
Why?
|
| Lead Poisoning, Nervous System, Childhood | 1 | 2010 | 18 | 0.090 |
Why?
|
| Ferritins | 2 | 2021 | 600 | 0.090 |
Why?
|
| Thiophenes | 1 | 2015 | 570 | 0.090 |
Why?
|
| Ion Transport | 1 | 2011 | 322 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15889 | 0.090 |
Why?
|
| Cerebral Arteries | 2 | 2010 | 489 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 9264 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2013 | 769 | 0.080 |
Why?
|
| Treatment Outcome | 13 | 2019 | 65480 | 0.080 |
Why?
|
| Prognosis | 5 | 2024 | 30046 | 0.080 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2010 | 82 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2020 | 8748 | 0.080 |
Why?
|
| Thinness | 1 | 2013 | 483 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2013 | 644 | 0.080 |
Why?
|
| Hyperkalemia | 1 | 2011 | 234 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 2414 | 0.080 |
Why?
|
| Pia Mater | 1 | 2009 | 87 | 0.080 |
Why?
|
| Serratia marcescens | 1 | 2008 | 48 | 0.080 |
Why?
|
| Retrospective Studies | 14 | 2024 | 81903 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 3928 | 0.080 |
Why?
|
| Pedigree | 4 | 2020 | 4545 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 505 | 0.070 |
Why?
|
| Length of Stay | 3 | 2018 | 6526 | 0.070 |
Why?
|
| Hemoglobin E | 1 | 2007 | 6 | 0.070 |
Why?
|
| Urinalysis | 1 | 2010 | 370 | 0.070 |
Why?
|
| Syndrome | 3 | 2021 | 3274 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2007 | 59 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 1434 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 5801 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 13021 | 0.070 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 39 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2016 | 2059 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3592 | 0.070 |
Why?
|
| Echoencephalography | 1 | 2007 | 134 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2017 | 2701 | 0.070 |
Why?
|
| Middle East | 2 | 2018 | 233 | 0.070 |
Why?
|
| Apoptosis | 1 | 2003 | 9527 | 0.070 |
Why?
|
| K562 Cells | 2 | 2020 | 648 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 1369 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2013 | 4794 | 0.070 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 1014 | 0.070 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2007 | 61 | 0.070 |
Why?
|
| Cholecystitis | 1 | 2007 | 181 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2018 | 2192 | 0.070 |
Why?
|
| Cerebral Revascularization | 1 | 2009 | 263 | 0.070 |
Why?
|
| Antigens, CD20 | 1 | 2007 | 199 | 0.070 |
Why?
|
| Bacteremia | 1 | 2013 | 985 | 0.070 |
Why?
|
| alpha-Thalassemia | 1 | 2006 | 53 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2011 | 1191 | 0.060 |
Why?
|
| Thrombosis | 1 | 2020 | 2956 | 0.060 |
Why?
|
| Self Care | 1 | 2011 | 801 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 10400 | 0.060 |
Why?
|
| Self Report | 1 | 2017 | 3773 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2007 | 642 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 4124 | 0.060 |
Why?
|
| Adult | 14 | 2020 | 223851 | 0.060 |
Why?
|
| Blood Flow Velocity | 3 | 2015 | 1376 | 0.060 |
Why?
|
| Moyamoya Disease | 1 | 2009 | 274 | 0.060 |
Why?
|
| Vancomycin | 1 | 2008 | 506 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2018 | 10115 | 0.060 |
Why?
|
| Liver | 2 | 2015 | 7578 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2007 | 409 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y12 | 2 | 2016 | 117 | 0.060 |
Why?
|
| Pleural Effusion | 1 | 2007 | 345 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 942 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2013 | 2167 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 696 | 0.060 |
Why?
|
| Drug Stability | 1 | 2004 | 292 | 0.050 |
Why?
|
| Solutions | 1 | 2004 | 410 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2016 | 4939 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2008 | 819 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4592 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 21547 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2007 | 667 | 0.050 |
Why?
|
| Normetanephrine | 1 | 2021 | 25 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1836 | 0.050 |
Why?
|
| Prednisone | 1 | 2007 | 1567 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2011 | 2421 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2008 | 712 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 5804 | 0.050 |
Why?
|
| Overweight | 1 | 2013 | 2448 | 0.050 |
Why?
|
| Models, Biological | 2 | 2015 | 9499 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2002 | 239 | 0.050 |
Why?
|
| Disease Management | 1 | 2012 | 2537 | 0.050 |
Why?
|
| Chromogranins | 1 | 2021 | 160 | 0.050 |
Why?
|
| Recurrence | 2 | 2018 | 8513 | 0.050 |
Why?
|
| Hemolysis | 1 | 2003 | 417 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2007 | 1070 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 1892 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 3713 | 0.040 |
Why?
|
| Heterozygote | 1 | 2007 | 2798 | 0.040 |
Why?
|
| Autistic Disorder | 1 | 2010 | 1240 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2003 | 855 | 0.040 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2020 | 85 | 0.040 |
Why?
|
| Survival Rate | 2 | 2012 | 12873 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4862 | 0.040 |
Why?
|
| Biological Transport | 1 | 2004 | 2085 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 3433 | 0.040 |
Why?
|
| Mass Screening | 3 | 2024 | 5457 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 388 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 2021 | 557 | 0.040 |
Why?
|
| Spinal Fusion | 1 | 2008 | 1313 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 2748 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2010 | 1542 | 0.040 |
Why?
|
| Europe | 2 | 2017 | 3441 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2020 | 393 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 39394 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 3 | 2015 | 2734 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2007 | 2120 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 1997 | 48 | 0.040 |
Why?
|
| Risk Factors | 5 | 2024 | 74976 | 0.040 |
Why?
|
| Risk | 2 | 2013 | 9621 | 0.040 |
Why?
|
| Benzylamines | 1 | 2018 | 251 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2007 | 2008 | 0.040 |
Why?
|
| Temperature | 1 | 2004 | 2235 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1997 | 236 | 0.030 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 263 | 0.030 |
Why?
|
| Acute Disease | 1 | 2007 | 7245 | 0.030 |
Why?
|
| Plasma | 1 | 2020 | 585 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 154 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2020 | 773 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 117 | 0.030 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2016 | 121 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2003 | 1855 | 0.030 |
Why?
|
| Patients | 1 | 2022 | 908 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 13510 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2126 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2017 | 211 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2010 | 6611 | 0.030 |
Why?
|
| Africa | 1 | 2017 | 726 | 0.030 |
Why?
|
| Middle Aged | 7 | 2018 | 223737 | 0.030 |
Why?
|
| Prevalence | 3 | 2021 | 15879 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 2057 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 656 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 36854 | 0.030 |
Why?
|
| Reticulocytes | 1 | 2014 | 288 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2003 | 4148 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 1866 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1586 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2020 | 2942 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1998 | 1266 | 0.030 |
Why?
|
| Boston | 2 | 2019 | 9377 | 0.030 |
Why?
|
| Age Factors | 3 | 2017 | 18435 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 17629 | 0.030 |
Why?
|
| RNA | 1 | 2003 | 2727 | 0.030 |
Why?
|
| Point Mutation | 1 | 2018 | 1596 | 0.030 |
Why?
|
| Cell Survival | 1 | 2003 | 5793 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2003 | 4032 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2015 | 291 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2003 | 2936 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 498 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3214 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2007 | 5919 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 1673 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 16053 | 0.030 |
Why?
|
| Time Factors | 3 | 2016 | 40261 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1839 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2013 | 422 | 0.020 |
Why?
|
| Exons | 1 | 2018 | 2395 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2024 | 22296 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 1767 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2016 | 2631 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2020 | 3412 | 0.020 |
Why?
|
| Cell Lineage | 2 | 2016 | 2576 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2011 | 192 | 0.020 |
Why?
|
| Asthma | 1 | 2010 | 6293 | 0.020 |
Why?
|
| Methylamines | 1 | 2011 | 136 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1813 | 0.020 |
Why?
|
| Gene Expression | 1 | 2003 | 7603 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 4712 | 0.020 |
Why?
|
| Body Weight | 1 | 2020 | 4628 | 0.020 |
Why?
|
| New England | 1 | 2013 | 1058 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2013 | 41808 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1998 | 2574 | 0.020 |
Why?
|
| United States | 5 | 2018 | 73186 | 0.020 |
Why?
|
| Binding Sites | 2 | 2013 | 6023 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2018 | 8094 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 927 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 387 | 0.020 |
Why?
|
| Zebrafish | 1 | 2020 | 3037 | 0.020 |
Why?
|
| Gallstones | 1 | 2011 | 285 | 0.020 |
Why?
|
| Registries | 2 | 2015 | 8384 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2003 | 9384 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2010 | 385 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 24333 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14484 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 4428 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3810 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 783 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 746 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 1104 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 11521 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1364 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 1973 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 463 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4290 | 0.020 |
Why?
|
| Outpatients | 1 | 2013 | 1603 | 0.020 |
Why?
|
| Caregivers | 1 | 2017 | 2308 | 0.010 |
Why?
|
| Transgenes | 2 | 1998 | 1016 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 7609 | 0.010 |
Why?
|
| Physicians | 1 | 2022 | 4607 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5369 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2013 | 13055 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5033 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2015 | 2055 | 0.010 |
Why?
|
| Markov Chains | 1 | 2007 | 979 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 3048 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8559 | 0.010 |
Why?
|
| Alleles | 1 | 2014 | 6901 | 0.010 |
Why?
|
| Organ Specificity | 2 | 1998 | 1970 | 0.010 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 1027 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 1204 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2009 | 1481 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 1665 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 4625 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2013 | 2784 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 22379 | 0.010 |
Why?
|
| Aged | 4 | 2016 | 171786 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 3775 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2016 | 19023 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2007 | 1249 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 15471 | 0.010 |
Why?
|
| Linear Models | 1 | 2010 | 5891 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1997 | 11932 | 0.010 |
Why?
|
| Animals | 4 | 2020 | 169335 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12095 | 0.010 |
Why?
|
| Sex Factors | 1 | 2013 | 10633 | 0.010 |
Why?
|
| Mice | 3 | 2020 | 82072 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23653 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13318 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 5716 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 6991 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 2528 | 0.010 |
Why?
|
| Base Composition | 1 | 1997 | 291 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 1998 | 296 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1998 | 1305 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 4265 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2010 | 6002 | 0.010 |
Why?
|
| Hospitals | 1 | 2010 | 3904 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 6435 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1998 | 1769 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2009 | 3008 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 1998 | 9565 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 812 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1997 | 1162 | 0.010 |
Why?
|
| Embryonic Development | 1 | 1997 | 724 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1997 | 1676 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15951 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 20245 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12801 | 0.010 |
Why?
|
| Obesity | 1 | 2013 | 13091 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1998 | 5906 | 0.000 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 3612 | 0.000 |
Why?
|
| Brain | 1 | 2014 | 27453 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1998 | 11684 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 30265 | 0.000 |
Why?
|